布基纳法索大规模阿奇霉素分发36个月后大环内酯类与非大环内酯类耐药性:整群随机试验
CHAT试验在布基纳法索Nouna区将社区按1:1随机分配至每年两次阿奇霉素(20 mg/kg)或安慰剂,36个月时对48个社区中每社区随机抽取15名儿童的直肠拭子行二代测序。
要点
- 每年两次阿奇霉素分发36个月未显著增加肠道大环内酯类耐药决定簇。
- β-内酰胺类等非大环内酯类耐药基因两组间亦无显著差异。
- 该结果支持在阿奇霉素分发项目中继续开展耐药监测。
核心结论
- 在布基纳法索该研究环境中,每年两次向1-59月龄儿童分发阿奇霉素在36个月时未导致大环内酯类或非大环内酯类遗传耐药决定簇出现统计学显著差异。
研究设计与样本
- CHAT为1:1整群随机安慰剂对照试验,2019至2023年在布基纳法索Nouna区开展。
- 社区按1:1随机接受每年两次阿奇霉素(20 mg/kg)或匹配安慰剂。
- 36个月时在参与试验的48个社区中每社区随机抽取15名儿童采集直肠拭子。
- 采用二代DNA测序评估耐药遗传决定簇。
主要发现
- 36个月时共分析来自41个社区的483份样本。
临床怎么用
- 提示在类似设置下每年两次阿奇霉素分发至36个月未显著选择肠道大环内酯类耐药。
- WHO建议在阿奇霉素分发背景下持续开展抗菌药物耐药监测,该试验支持监测的必要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biannual mass azithromycin distribution to children aged 1-59 months reduces all-cause child mortality but selects for antimicrobial resistance (AMR). The World Health Organization (WHO) recommends ongoing surveillance of AMR in the context of azithromycin distribution. We evaluated the impact of twice-yearly distribution of azithromycin compared to placebo on AMR in the gut of children in Burkina Faso. METHODS: The Community Health with Azithromycin Trial (CHAT) was a 1:1 cluster randomized placebo-controlled trial in Nouna District, Burkina Faso, from 2019 to 2023. Communities were randomized in a 1:1 fashion to twice-yearly azithromycin (20 mg/kg) or matching placebo. At 36 months, rectal swabs were collected from a random sample of 15 children per community in 48 communities participating in the trial and assessed for AMR genetic resistance determinants using next-generation DNA sequencing (DNA-seq). We assessed the fold-change in macrolide and nonmacrolide resistance determinants between treatment groups after 36 months. RESULTS: A total of 483 samples from 41 communities were analyzed at 36 months. There was no evidence of a difference in macrolide resistance determinants in the azithromycin group compared to the placebo group (fold-change, 1.21; 95% confidence interval [CI], .96-1.52; P = .62). There was no evidence of a difference in nonmacrolide resistance genes; for example, beta-lactam resistance was similar between treatment groups (fold-change, 1.05; 95% CI, .79-1.40; P = .81). CONCLUSIONS: In this setting in Burkina Faso, twice-yearly azithromycin distributions to children aged 1-59 months did not lead to statistically significant differences in macrolide or nonmacrolide genetic resistance determinants at 36 months. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT03676764.
引用
- Oldenburg CE, Coulibaly B, Sié A, et al. Macrolide and Nonmacrolide Resistance After 36 Months of Mass Azithromycin Distribution in Burkina Faso: A Cluster Randomized Trial. Clin Infect Dis. 2026. PMID: 41626759. doi:10.1093/cid/ciag051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。